Ars Pharmaceuticals, Inc. (SPRY) fundamentals score
neffy and EURneffy are trademarks of its that Ars Pharmaceuticals uses in this Annual Report. This Annual Report also includes trademarks, trade names, and service marks that are the property of other organizations.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.3 out of 10, Weak long-term fundamentals
- Growth: 6.0/10
- Profitability: 1.0/10
- Financial health: 5.0/10
- Earnings quality: 5.9/10
- Valuation: 4.3/10
Scores are calculated from Ars Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10